Myriad Genetics, Inc. (MYGN): ANSOFF MATRIX ANÁLISE [JAN-2025 Atualizado]

No cenário em rápida evolução da medicina de precisão, a Myriad Genetics, Inc. está na vanguarda das estratégias de testes genéticos transformadores. Ao elaborar meticulosamente uma matriz abrangente de Ansoff, a empresa traça um curso ambicioso na penetração do mercado, desenvolvimento, inovação de produtos e diversificação estratégica. Essa abordagem dinâmica não apenas promete revolucionar a triagem genética e a assistência médica personalizada, mas também posiciona uma infinidade de genética como uma força pioneira no desbloqueio do intrincado potencial de idéias genéticas, oferecendo um vislumbre de um futuro em que diagnósticos moleculares avançados podem remodelar fundamentalmente o atendimento ao paciente e o entendimento médico.

Myriad Genetics, Inc. (Mygn) - Ansoff Matrix: Penetração de mercado

Expanda o volume de testes genéticos no mercado de oncologia

A Miríade Genetics registrou US $ 629,4 milhões em receita total para o ano fiscal de 2022, com testes de câncer hereditários representando uma parcela significativa.

Aumentar o engajamento da força de vendas

Miríade genética mantém uma força de vendas direta de 187 representantes direcionados aos centros de oncologia em todo o país.

• 2.345 prestadores de serviços de saúde cobertos
• Relacionamentos estabelecidos com 612 centros de oncologia
• Interação média de vendas: 43 reuniões por representante mensal

Desenvolva modelos de preços estratégicos

O preço dos testes genéticos atuais varia de US $ 349 a US $ 4.500, dependendo da complexidade.

Aprimore os programas de retenção de clientes

Taxa atual de retenção de clientes: 68,3% para clientes de testes genéticos.

• Protocolos de acompanhamento personalizados implementados
• Programas de apoio aos pacientes desenvolvidos
• Criou plataformas de engajamento de pacientes digitais

Marketing direto ao consumidor para triagem hereditária de risco de câncer

Investimento de marketing: US $ 42,6 milhões em 2022 para campanhas diretas ao consumidor.

Myriad Genetics, Inc. (Mygn) - Anoff Matrix: Desenvolvimento de Mercado

Expanda o alcance geográfico para os mercados internacionais

A Myriad Genetics registrou receita internacional de US $ 37,5 milhões no ano fiscal de 2022, representando 16,5% da receita total da empresa. A penetração do mercado europeu aumentou 7,2% no mesmo período.

Direcionar novos segmentos de saúde

Tamanho do mercado de testes de fertilidade projetado para atingir US $ 1,2 bilhão até 2025. O segmento de saúde reprodutiva da Myriad cresceu 12,4% em 2022.

• Mercado de Clínicas de Fertilidade: 18,3% de taxa de crescimento anual
• Receita de testes de saúde reprodutiva: US $ 45,6 milhões

Desenvolva parcerias com redes hospitalares

A rede de parceria atual inclui 237 sistemas hospitalares. Os acordos de pesquisa colaborativa aumentaram 15 em 2022.

Explore os mercados emergentes

O mercado de medicina de precisão deve atingir US $ 196,2 bilhões globalmente até 2026. Os investimentos emergentes do mercado totalizaram US $ 12,3 milhões em 2022.

Adaptar ofertas de testes genéticos

Investimentos de conformidade regulatória de US $ 8,7 milhões em 2022. Obteve com sucesso 14 novas certificações regionais de saúde.

• Gastos de conformidade regulatória: US $ 8,7 milhões
• Novas certificações regionais: 14

Myriad Genetics, Inc. (Mygn) - Anoff Matrix: Desenvolvimento de Produtos

Invista em tecnologias avançadas de diagnóstico molecular para triagem de câncer

Em 2022, a Miríade Genetics investiu US $ 78,3 milhões em P&D para tecnologias avançadas de diagnóstico molecular. O portfólio de triagem de câncer genético da empresa gerou US $ 342,5 milhões em receita.

Desenvolver novos painéis genéticos direcionados a distúrbios genéticos raros

A Myriad desenvolveu 7 novos painéis genéticos para distúrbios raros em 2022, cobrindo aproximadamente 150 condições genéticas únicas.

• Custo de desenvolvimento do painel de transtornos raros: US $ 12,6 milhões
• Tamanho estimado do mercado para testes raros de transtorno genético: US $ 475 milhões
• Número de novas condições genéticas identificadas: 38

Crie soluções de medicina personalizadas integrando insights genéticos

As soluções de medicina personalizadas geraram US $ 214,7 milhões em receita para a Miríade em 2022.

Aprimore os recursos de bioinformática

A Myriad investiu US $ 56,4 milhões em infraestrutura de bioinformática em 2022, processando mais de 1,2 milhão de testes genéticos.

• Análise computacional Velocidade: 15.000 perfis genéticos por dia
• Algoritmo de aprendizado de máquina precisão: 94,7%
• Capacidade de armazenamento de dados: 3.8 petabytes

Expanda testes de farmacogenômica

Os testes de farmacogenômica expandidos para cobrir 62 categorias de medicamentos diferentes em 2022.

Myriad Genetics, Inc. (Mygn) - Ansoff Matrix: Diversificação

Aquisições estratégicas em domínios de tecnologia genética complementares

Em 2019, a Myriad Genetics adquiriu a Assurex Health por US $ 225 milhões, expandindo seu portfólio de medicamentos de precisão. A empresa registrou US $ 874,2 milhões em receita total para o ano fiscal de 2022.

Plataformas de saúde digital integrando dados genéticos e insights de pacientes

A Myriad investiu US $ 86,4 milhões em pesquisa e desenvolvimento em 2022, com foco no desenvolvimento da plataforma digital.

• MyRisk Hereditary Cancer Platform cobre 11 tipos de câncer
• O banco de dados de testes genéticos contém mais de 5 milhões de registros de pacientes

Ferramentas de avaliação de risco genético preditivo acionado por IA

A empresa alocou 13,4% de sua receita total à pesquisa e desenvolvimento em 2022.

Soluções de teste genético para especialidades médicas emergentes

Miríade expandiu os serviços de testes genéticos em várias especialidades médicas, gerando US $ 874,2 milhões em 2022 receita.

• Participação de mercado de testes genéticos de oncologia: 25%
• Testes genéticos de saúde reprodutiva: receita de segmento de US $ 310 milhões

Serviços educacionais e de consultoria para interpretação de testes genéticos

A Myriad desenvolveu serviços abrangentes de aconselhamento genético com 150 conselheiros genéticos certificados na equipe.

Myriad Genetics, Inc. (MYGN) - Ansoff Matrix: Market Penetration

Drive GeneSight test volume growth by 20% in the US.

For the third quarter of 2025, GeneSight test volume grew 8% year-over-year. This reflects ongoing improvement from the second quarter of 2025, where GeneSight test volume growth was 5% year-over-year. This growth follows the impact of UnitedHealthcare's discontinuation of coverage effective in the first quarter of 2025.

Increase myRisk hereditary cancer test adoption in underserved US populations.

Hereditary cancer testing volume for the unaffected population increased 11% year-over-year in the third quarter of 2025. In the second quarter of 2025, MyRisk with RiskScore testing volume in oncology grew 14% year-over-year. A recent survey indicated that 37% of women surveyed believe genetic testing can help manage breast health, yet only 14% of respondents reported having undergone genetic testing.

Secure broader payer coverage for Prolaris prostate cancer test in regional plans.

Historically, Prolaris achieved insurance coverage for approximately 50 percent of Prostate cancer patients in the United States, later increasing to cover more than 55 percent of eligible patients. The company continues working with remaining private health insurers to expand access.

Expand telehealth integration to simplify physician ordering and patient access.

Myriad Genetics' full oncology portfolio of germline and tumor genomic tests is expected to be fully integrated with both Flatiron's OncoEMR and Epic cloud-based platforms later this year in 2025. The company offers electronic medical record (EMR) integration to help providers order tests and access results directly within their daily platforms. The partnership with Epic aims to scale tech-enabled commercial capabilities.

Offer bundled testing options to increase average revenue per patient.

In the second quarter of 2025, gross margin benefited from improving average revenue per test trends. However, the first quarter of 2025 saw a year-over-year decrease in the average revenue per hereditary cancer test, largely due to a difference in the change in estimated revenue related to prior periods.

Here's a quick look at recent operational metrics:

The company's strategy involves several key areas to drive penetration:

• Use of EMR solutions for breast cancer risk assessment programs.
• Launching an expanded gene panel for the MyRisk Hereditary Cancer Test later in 2025.
• Entering a collaboration with SOPHiA GENETICS for CDx development services.
• Anticipating the commercial launch of the Precise MRD assay in 2026.
• Planning the launch of the Prolaris test with PATHOMIQ's AI technology in early 2026.

Finance: review the impact of the new $200 million credit facility on Q4 2025 interest expense by Thursday.

Myriad Genetics, Inc. (MYGN) - Ansoff Matrix: Market Development

Accelerate GeneSight launch and reimbursement efforts across major European markets. The Pharmacogenomics revenue segment saw a 20% year-over-year decline in the first quarter of 2025, directly attributed to UnitedHealthcare reducing coverage for GeneSight®.

Establish strategic distribution partnerships in Japan and South Korea for myRisk. Myriad International Offices currently list a presence in Japan as Myriad Genetics G.K..

Target international revenue to reach 15% of total revenue within two years.

Obtain regulatory approvals for Foresight carrier screening in Canada and Australia. The Foresight® Carrier Screen was included in research studies presented at the National Society of Genetic Counselors Annual Conference in November 2025.

Focus sales teams on large, integrated health systems outside the US. The company completed the sale of its international EndoPredict business in August 2024.

Here's the quick math on how the core business performed in 2025, which sets the stage for international focus:

The Hereditary Cancer testing volume in the third quarter of 2025 increased 11% year-over-year, which includes myRisk testing.

The company is working on several product launches that could impact future international market entry:

• AI-enabled Prolaris test targeted for year-end 2025.
• PRECISE MRD targeted for a first-half 2026 launch.
• Commercially launching FirstGene Multiple Prenatal Screen in 2026.

The overall 2025 revenue guidance range was revised to between $807 million and $823 million after the first quarter.

Finance: draft 13-week cash view by Friday.

Myriad Genetics, Inc. (MYGN) - Ansoff Matrix: Product Development

You're looking at how Myriad Genetics, Inc. (MYGN) plans to grow by launching new products into existing markets, which is the Product Development quadrant of the Ansoff Matrix. We need to ground this in the numbers they've reported through the third quarter of 2025.

For the commitment to innovation, while the target of $100 million annually in R&D isn't explicitly confirmed in the latest filings, we see the trend. Research and development expense for the full year ended December 31, 2024, increased by $24.7 million compared to the prior year, driven by investments in new products like the MRD test. This investment focus continued into 2025; for instance, Q1 2025 adjusted operating expenses of $140.6 million reflected maintaining investments in key strategic areas, including research and development. This shows the ongoing financial commitment to pipeline advancement.

The next-generation version of myRisk Hereditary Cancer Test saw a significant upgrade as of November 10, 2025. The panel expanded to 63 genes, covering more than 11 cancer types. This update means the test now includes 100% of genes strongly recommended by national oncology guidelines like NCCN and ASCO. This enhancement was achieved by adding 15 newly added guideline-recommended genes and 36 evidence-based intronic variants.

Here's a snapshot of the myRisk expansion:

In prostate cancer diagnostics, Myriad Genetics, Inc. is integrating artificial intelligence (AI) into the Prolaris test. The plan is to launch the first AI-driven prostate cancer clinical test, which integrates PATHOMIQ's AI technology, later in 2025 (with some forward-looking statements suggesting early 2026). This AI platform analyzes digitized H&E whole slide images to predict disease recurrence after initial therapy. The technology is designed to deliver results within 1-2 days after receiving digital patient samples. The collaboration aims to accelerate achieving Simon level 1 evidence for both the Prolaris and the AI component. Prolaris testing revenue itself showed growth of 3% year-over-year in the third quarter of 2025.

Regarding companion diagnostics for oncology drugs, Myriad Genetics, Inc. announced a strategic collaboration on September 23, 2025, with SOPHiA GENETICS to develop an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad's advanced laboratory capabilities in the US to support clinical trials testing. The initial focus is on the MSK-ACCESS® powered with SOPHiA DDM™ liquid biopsy application. SOPHiA GENETICS supports global deployment through a network of more than 800 connected institutions across over 70 countries.

The development pipeline also includes other areas, though specific financial or launch metrics for a new mental health screening test weren't detailed in the latest reports. However, other product lines show activity, such as the Pharmacogenomics segment revenue declining by 20% in Q1 2025 and (19)% in Q3 2025, signaling a need for new product introductions in that space to offset coverage headwinds, like the UnitedHealthcare reduction. The Prenatal segment, conversely, showed strength, with revenue growing 11% in Q1 2025.

Here are the revenue performance indicators for context on where new products need to drive growth:

• Q3 2025 Hereditary Cancer Revenue: $81.8 million (up 2% year-over-year).
• Q3 2025 Hereditary Cancer Volume: Increased 9% year-over-year.
• Q1 2025 Pharmacogenomics Revenue: $31.0 million (down 20% year-over-year).
• Q2 2025 Hereditary Cancer Volume (Oncology): Grew 10% year-over-year.

Myriad Genetics, Inc. (MYGN) - Ansoff Matrix: Diversification

You're looking at how Myriad Genetics, Inc. (MYGN) can push beyond its core genetic testing base, which is smart given the competitive landscape. Diversification here means moving into new markets or offering new services, which is where the real upside often hides. We are mapping potential moves against a contextual revenue scale of $700 million, aiming for $50 million in new contribution from these efforts.

For context on M&A as a diversification tool, look at past moves. The acquisition of Assurex Health in 2016 was for an upfront cost of $225 million, with potential performance-based milestones reaching $185 million. Assurex generated over $60 million in revenue in Myriad Genetics, Inc.'s fiscal year 2016. More recently, the Counsyl, Inc. acquisition in 2018 was valued at $375 million, which immediately positioned Myriad Genetics, Inc. as a premier Women's Health organization.

Entering the direct-to-consumer (DTC) wellness market with a new, non-diagnostic service is a classic diversification play. Myriad Genetics, Inc. has experience here through the acquisition of Gateway Genomics for $67.5 million, which brought the SneakPeek® Early Gender DNA Test. That test had shown a compound annual growth rate exceeding 20% over the three years prior to the acquisition. This shows a path to scaling a non-diagnostic, consumer-facing offering quickly.

For clinical trial services, Myriad Genetics, Inc. already has deep regulatory experience across the United States, Europe, and Japan. A recent, concrete step is the strategic collaboration announced in September 2025 with SOPHiA GENETICS to develop a global liquid biopsy companion diagnostic (CDx) test. This partnership leverages Myriad Genetics, Inc.'s advanced U.S. laboratory capabilities to support global testing for clinical trials, while SOPHiA GENETICS manages regulatory submissions outside the U.S. This is a tangible move into expanding biopharma services globally.

Developing a new platform for infectious disease monitoring, a new market, is aggressive. While specific infectious disease platform details aren't immediately clear, Myriad Genetics, Inc. is actively developing its Minimal Residual Disease (MRD) testing platform, which is tumor-informed and uses whole-genome sequencing. This platform tracks up to thousands of variants, which is significantly more sensitive than the 50 or fewer variants monitored by most current MRD tests. The Precise MRD assay is planned for a controlled early access launch in 2026. This demonstrates capability in developing entirely new, high-tech platforms for new clinical questions.

To hit the required revenue targets, you need to see where the current business stands against the goal. Full-year 2024 revenue was approximately $838 million, and the reaffirmed 2025 guidance is between $818 million and $828 million. Still, the diversification goal is framed against a $700 million scale. Here's the quick math on how the $50 million target fits into the current business mix, using the 2025 guidance midpoint of $823 million for comparison, even though the prompt specified $700 million as the base for the target.

Achieving the $50 million from new streams means that, relative to the $700 million context, diversification needs to account for approximately 7.14% of that revenue base. The actual revenue base in 2024 was higher at $837.60 million, meaning the actual required percentage of the actual revenue would be closer to 5.97% (50 / 837.60). What this estimate hides is the required investment spend to generate that $50 million, which could impact near-term profitability, as seen by the Q3 2025 adjusted EPS of $0.00.

These diversification avenues require specific execution focus:

• Acquisition: Due diligence on cardiology market size and integration costs.
• DTC Wellness: Scaling digital marketing spend to capture the 4 million annual SneakPeek website visitors.
• Pharma Partnership: Securing 10 companion diagnostic approvals in the U.S. and Japan as a benchmark.
• New Platform: Successfully transitioning the Precise MRD assay from research evaluation to commercial use in 2026.

Finance: draft 13-week cash view by Friday.